[go: up one dir, main page]

IL126546A - Composition comprising aryl-piperazinyl-hetrocyclic salts and cyclodextrin - Google Patents

Composition comprising aryl-piperazinyl-hetrocyclic salts and cyclodextrin

Info

Publication number
IL126546A
IL126546A IL12654697A IL12654697A IL126546A IL 126546 A IL126546 A IL 126546A IL 12654697 A IL12654697 A IL 12654697A IL 12654697 A IL12654697 A IL 12654697A IL 126546 A IL126546 A IL 126546A
Authority
IL
Israel
Prior art keywords
hetrocyclic
cyclodextrin
piperazinyl
aryl
salts
Prior art date
Application number
IL12654697A
Other languages
English (en)
Other versions
IL126546A0 (en
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL126546A0 publication Critical patent/IL126546A0/xx
Publication of IL126546A publication Critical patent/IL126546A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pyridine Compounds (AREA)
  • Seasonings (AREA)
  • Machine Translation (AREA)
  • Soil Conditioners And Soil-Stabilizing Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL12654697A 1996-05-07 1997-04-01 Composition comprising aryl-piperazinyl-hetrocyclic salts and cyclodextrin IL126546A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1920496P 1996-05-07 1996-05-07
PCT/IB1997/000321 WO1997041896A2 (en) 1996-05-07 1997-04-01 Inclusion complexes of aryl-heterocyclic salts

Publications (2)

Publication Number Publication Date
IL126546A0 IL126546A0 (en) 1999-08-17
IL126546A true IL126546A (en) 2001-01-28

Family

ID=21791976

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12654697A IL126546A (en) 1996-05-07 1997-04-01 Composition comprising aryl-piperazinyl-hetrocyclic salts and cyclodextrin

Country Status (47)

Country Link
US (2) US6232304B1 (sr)
EP (1) EP0900088B1 (sr)
JP (1) JP3579060B2 (sr)
KR (1) KR20000010823A (sr)
CN (1) CN1216923A (sr)
AP (1) AP796A (sr)
AR (2) AR007002A1 (sr)
AT (1) ATE257714T1 (sr)
AU (1) AU713711B2 (sr)
BG (3) BG64474B1 (sr)
BR (1) BR9709213A (sr)
CA (1) CA2251912C (sr)
CO (1) CO4600677A1 (sr)
CZ (1) CZ297847B6 (sr)
DE (1) DE69727218T2 (sr)
DK (1) DK0900088T3 (sr)
DZ (1) DZ2220A1 (sr)
EA (1) EA001731B1 (sr)
EG (1) EG24135A (sr)
ES (1) ES2212809T3 (sr)
GE (1) GEP20074185B (sr)
GT (1) GT199700044A (sr)
HN (1) HN1997000039A (sr)
HR (1) HRP970237B1 (sr)
HU (1) HU222451B1 (sr)
ID (1) ID16866A (sr)
IL (1) IL126546A (sr)
IS (1) IS2524B (sr)
MA (1) MA24172A1 (sr)
ME (1) ME00880B (sr)
MY (1) MY121999A (sr)
NO (1) NO324373B1 (sr)
NZ (1) NZ332220A (sr)
OA (1) OA10907A (sr)
PL (1) PL189324B1 (sr)
PT (1) PT900088E (sr)
RS (1) RS49532B (sr)
SA (1) SA97180024B1 (sr)
SI (1) SI0900088T1 (sr)
SK (1) SK282032B6 (sr)
TN (1) TNSN97075A1 (sr)
TR (1) TR199802231T2 (sr)
TW (1) TW514529B (sr)
UA (1) UA57734C2 (sr)
UY (1) UY24544A1 (sr)
WO (1) WO1997041896A2 (sr)
ZA (1) ZA973874B (sr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0811386B1 (en) * 1996-05-07 2004-09-29 Pfizer Inc. Method of selecting a salt for making an inclusion complex
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
JP4503724B2 (ja) * 1999-05-10 2010-07-14 栄研化学株式会社 ホタルルシフェリンの安定化方法
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US6884885B2 (en) 2000-12-21 2005-04-26 Cerestar Holding B.V. Production of cyclodextrin complexes
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
US6869939B2 (en) * 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
WO2004017897A2 (en) * 2002-08-20 2004-03-04 Bristol-Myers Squibb Company Aripiprazole complex formulation and method
EP1546143A1 (en) * 2002-09-17 2005-06-29 Warner-Lambert Company LLC Heterocyclic substituted piperazines for the treatment of schizophrenia
PL375603A1 (en) * 2002-10-25 2005-12-12 Pfizer Products Inc. Depot formulations of arylheterocyclic active agents in the form of a suspension
PL377679A1 (pl) * 2002-10-25 2006-02-06 Pfizer Products Inc. Nowe preparaty typu depot do wstrzykiwania
JP2006506397A (ja) * 2002-10-31 2006-02-23 ファイザー・プロダクツ・インク 固体及び半固体高分子イオン・コンジュゲート
CA2504345A1 (en) * 2002-10-31 2004-05-13 Pfizer Products Inc. Liquid conjugates of solid pharmaceuticals
MXPA03009945A (es) * 2002-11-05 2007-04-16 Lg Electronics Inc Montaje para montar una pantalla de toque para un monitor con pantalla de cristal liquido.
CN1255105C (zh) * 2002-12-17 2006-05-10 上海医药工业研究院 齐拉西酮及其盐的水溶性包合物及其制备方法
US20050043324A1 (en) * 2003-06-03 2005-02-24 Tamas Koltai Polymorphic forms of ziprasidone HCI and processes for their preparation
JP2007504266A (ja) * 2003-09-02 2007-03-01 ファイザー・プロダクツ・インク ジプラシドンの持続放出剤形
EP1691801A4 (en) * 2003-12-08 2009-12-09 Univ Arizona State SYNERGISTIC ANTI-CANCER COMPOSITIONS
US20050163858A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Ziprasidone formulations
SI21703A (en) * 2004-01-14 2005-08-31 Lek Farmacevtska Druzba Dd Inclusion complexes of perindopril, procedure of their preparation, pharmaceutical compositions containing these complexes and their application in treatment of hypertensia
WO2005107719A2 (en) 2004-05-06 2005-11-17 Sandoz Ag Pharmaceutical composition comprising hydrophobic drug having improved solubility
WO2006032957A1 (en) * 2004-05-26 2006-03-30 Pfizer Products Inc. In vitro predictive method
EP1753400A4 (en) * 2004-06-11 2012-11-28 Reddys Lab Ltd Dr PHARMACEUTICAL FOR ZIPRASIDONE
KR20130030305A (ko) * 2004-11-16 2013-03-26 엘란 파마 인터내셔널 리미티드 주사가능한 나노입자형 올란자핀 제형
WO2006086779A1 (en) * 2005-02-11 2006-08-17 Teva Pharmaceutical Industries Ltd. Amorphous ziprasidone mesylate
EP1855651A4 (en) * 2005-03-03 2011-06-15 Elan Pharma Int Ltd NANOPARTICULAR COMPOSITIONS OF HETEROCYCLIC AMIDE DERIVATIVES
WO2006098834A2 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
US20060270685A1 (en) * 2005-03-14 2006-11-30 Judith Aronhime Anhydrous ziprasidone mesylate and a process for its preparation
US20070191306A1 (en) * 2005-08-17 2007-08-16 Bristol-Myers Squibb Company FACTOR Xa INHIBITOR FORMULATION AND METHOD
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
CN100391458C (zh) * 2006-02-07 2008-06-04 上海医药工业研究院 齐拉西酮或其盐包合物制备方法
WO2008007071A1 (en) 2006-07-10 2008-01-17 Cenes Limited Short-acting benzodiazepine salts and their polymorphic forms
CN101677568A (zh) * 2007-05-18 2010-03-24 赛多斯有限责任公司 齐拉西酮制剂
US8192721B2 (en) * 2007-12-13 2012-06-05 Verrow Pharmaceuticals, Inc. Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
CN101314045B (zh) * 2008-05-09 2013-01-23 沈阳药科大学 桂利嗪的磺丁基醚-β-环糊精包合物及其制剂和制备方法
WO2011148253A2 (en) 2010-05-25 2011-12-01 Aurobindo Pharma Limited Solid dosage forms of antipsychotics
EP2450039A1 (en) 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
CN102793701B (zh) * 2011-05-25 2014-12-17 上海医药工业研究院 卢拉西酮组合物
TW201332572A (zh) 2011-12-28 2013-08-16 Otsuka Pharma Co Ltd 具有經取代的β－環糊精之藥物製劑
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
WO2023108156A1 (en) * 2021-12-11 2023-06-15 Beloteca, Inc. Ziprasidone formulations

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) * 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
IT1196033B (it) 1984-02-22 1988-11-10 Chiesi Farma Spa Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche
MX173362B (es) 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US4883795A (en) 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
IT1255462B (it) 1992-07-28 1995-11-02 Grazia Maffione Metodo di preparazione di composti di inclusione di nimesulide con ciclodestrine
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
IT1263831B (it) 1993-01-29 1996-09-04 Paolo Chiesi Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
HU210922B (en) 1993-05-24 1995-09-28 Europharmaceuticals Sa Nimesulide alkali salt cyclodextrin inclusion complexes their preparation and pharmaceutical compositions containing them
IT1269578B (it) 1994-04-22 1997-04-08 Chiesi Farma Spa Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base.
BE1008307A3 (fr) 1994-06-16 1996-04-02 Europharmaceuticals Sa Sel de nimesulide hydrosoluble, solution aqueuse le contenant, sa preparation et son utilisation.
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
PL188164B1 (pl) 1996-05-07 2004-12-31 Pfizer Trihydrat metanosulfonianu 5-{2-[4-1,2-benzizotiazol-3-ilo)-1-piperazynylo]etylo}-6-chloro-1,3-dihydro-2H-indol-2-onu i środek farmaceutyczny
EP0811386B1 (en) 1996-05-07 2004-09-29 Pfizer Inc. Method of selecting a salt for making an inclusion complex
JPH10194996A (ja) * 1996-12-25 1998-07-28 Janssen Pharmaceut Nv アシル化シクロデキストリン含有製薬組成物

Also Published As

Publication number Publication date
AR007002A1 (es) 1999-10-13
DK0900088T3 (da) 2004-04-19
PT900088E (pt) 2004-04-30
AU713711B2 (en) 1999-12-09
AP9700977A0 (en) 1997-07-31
WO1997041896A3 (en) 1998-01-08
IS4880A (is) 1998-10-27
MA24172A1 (fr) 1997-12-31
ZA973874B (en) 1998-11-06
JPH11509866A (ja) 1999-08-31
JP3579060B2 (ja) 2004-10-20
UY24544A1 (es) 2000-09-29
BG64475B1 (bg) 2005-04-30
US20010031756A1 (en) 2001-10-18
CN1216923A (zh) 1999-05-19
EG24135A (en) 2008-08-06
HU222451B1 (hu) 2003-07-28
HRP970237A2 (en) 1998-12-31
TR199802231T2 (xx) 1999-02-22
BG64474B1 (bg) 2005-04-30
TNSN97075A1 (fr) 2005-03-15
IS2524B (is) 2009-07-15
NO985192L (no) 1998-11-06
SK282032B6 (sk) 2001-10-08
SK150498A3 (en) 2000-01-18
CA2251912C (en) 2003-06-03
DZ2220A1 (fr) 2002-12-03
EA001731B1 (ru) 2001-08-27
UA57734C2 (uk) 2003-07-15
GEP20074185B (en) 2007-08-10
AP796A (en) 1999-12-24
NZ332220A (en) 2000-03-27
DE69727218T2 (de) 2004-11-18
ATE257714T1 (de) 2004-01-15
PL329928A1 (en) 1999-04-26
KR20000010823A (ko) 2000-02-25
WO1997041896A2 (en) 1997-11-13
BG102894A (en) 1999-09-30
SA97180024B1 (ar) 2005-12-24
CZ297847B6 (cs) 2007-04-11
HRP970237B1 (en) 2002-04-30
GT199700044A (es) 1998-10-02
ES2212809T3 (es) 2004-08-01
CO4600677A1 (es) 1998-05-08
EP0900088A2 (en) 1999-03-10
TW514529B (en) 2002-12-21
AR045528A2 (es) 2005-11-02
HUP9902799A2 (hu) 1999-12-28
PL189324B1 (pl) 2005-07-29
SI0900088T1 (en) 2004-04-30
OA10907A (en) 2001-10-26
CA2251912A1 (en) 1997-11-13
NO985192D0 (no) 1998-11-06
RS49532B (sr) 2006-12-15
EP0900088B1 (en) 2004-01-14
DE69727218D1 (de) 2004-02-19
ME00880B (me) 2006-12-15
AU1937297A (en) 1997-11-26
MY121999A (en) 2006-03-31
YU17297A (sh) 1999-12-27
NO324373B1 (no) 2007-10-01
IL126546A0 (en) 1999-08-17
BR9709213A (pt) 1999-08-10
HUP9902799A3 (en) 2000-12-28
BG64475B2 (bg) 2005-04-30
CZ346198A3 (cs) 1999-09-15
HN1997000039A (es) 1997-06-26
US6232304B1 (en) 2001-05-15
US6399777B2 (en) 2002-06-04
EA199800910A1 (ru) 1999-04-29
ID16866A (id) 1997-11-20

Similar Documents

Publication Publication Date Title
IL126546A (en) Composition comprising aryl-piperazinyl-hetrocyclic salts and cyclodextrin
AU4208799A (en) Interleukins-21 and 22
PL327659A1 (en) Disinfecting compositions and surface disinfecting methods
GB9612067D0 (en) Composition
GB9624874D0 (en) Composition
GB9813271D0 (en) Composition and use
GB9601398D0 (en) Composition
GB9612595D0 (en) Composition
ZA200101933B (en) Novel composition and use
HK1033653A1 (en) Synergistic composition and use thereof
PL328463A1 (en) Disinfecting composition and surface disinfecting methods
EP0739623A4 (en) DERMATOLOGICAL PREPARATION
ZA976791B (en) Composition comprising mupirocin and chlohexidine
GB9605247D0 (en) Composition
GB9619074D0 (en) Composition
GB9602266D0 (en) Composition
PL331523A1 (en) Azolotrizines and azolopyrimidines
PL328334A1 (en) Preparation and application thereof
GB9610966D0 (en) Composition
AU3868497A (en) Benzenesulfone compounds and salts thereof
AU691690B2 (en) Acrolein-releasing composition and use thereof
HUP9900068A3 (en) Fuse-switch and/or fuse-disconnector
GB9413076D0 (en) Composition and use
GB9805172D0 (en) Composition and use
GB9722392D0 (en) Composition and use

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
RH1 Patent not in force